What is Hit Identification?

Hit identification is the most critical step in identifying compounds capable of interacting with a fully validated target. The strategy must ensure that it reduces the number of potential false positives. This will reduce the risk of identifying a series of compounds that are not suitable for development, spending resources on the wrong compound. Successful hit identification campaigns rely on using high-quality, diverse libraries of compounds to screen, while also leveraging other complementary techniques such as virtual screening and fragment-based screening. This must be coupled with the most relevant and accurate deployment of analytics for specific targets and disease states. Nowadays, virtual screening, traditional high-throughput screening, and fragment-based screening are now established as three critical hit-calling paradigms in drug discovery.

How does Ace Therapeutics Identify Ophthalmic Small Molecule Compounds With Confirmed Activity Against Drug Targets?

Once a drug target is identified, a key determinant of the success of a research program will be the quality of the small molecule hits. Ace Therapeutics' dedicated team has decades of experience in hit identification utilizing all modern techniques, including the chemistry and biology required to identify and improve high-quality hit sequences. Our team has always believed that generating higher quality hits will ultimately lead to faster discovery of better drug candidates. This will save you time and money by giving you a quality end product. Our scientists can develop different methods and run them sequentially or in parallel for superior results. During our hit identification process, hit sequences must undergo a dedicated design and series of assays, which reduces the risk of identifying a series of compounds that are not suitable for development, and ultimately only the most promising series will enter the hit-to-lead stage.

Services Overview

Ace Therapeutics has a number of methods for discovering ophthalmic small-molecule leads. We use a variety of techniques for hit identification, including fragment-based drug design, virtual screening, lead literature or high-throughput screening, among others. Our team of experts selects one or more methods to use to generate your novel chemical of interest. Our comprehensive discovery platform gives you an early advantage over your competitors. Here, Ace Therapeutics offers the following hit identification services, including but not limited to.

• Virtual Screening
• Ligand-Based Virtual Screening
• Fragment-Based Virtual Screening
• Phenotype-Based Virtual Screening
• Structure-Based Screening
• High-Throughput Screening
• Computer-Aided Screening
• Compound Library

Why Choose Us?

Ace Therapeutics has long experience in ophthalmic small molecule lead discovery. We can easily provide you with small molecule compounds that have many of the characteristics you are looking for in your final drug. Our team supports your hit identification efforts through strategy design, assay development, and screening activities. In addition, we have significant advantages when it comes to ophthalmic small molecule lead compound hits, which will save you a lot of time and money.

• Develop and implement customized strategies for global clients to maximize the chances of success.
• Assay development based on specific characteristics of client targets and ophthalmic diseases of interest.
• Provide protein, peptide or fragment screening for validation and testing purposes.
• Advanced technology platform, high-throughput screening equipment covering multiple detection technologies.
• Extensive library of selected compounds.
• Robust, feasible screening strategy.
• Automated screening process to reduce human error.
• Experienced medicinal chemistry team.

Ace Therapeutics has a team of scientists in the field of hit identification who are able to use a variety of advanced identification methods for your project. Along the way, once we have identified a hit to your target of interest, we can continue to support your project into the next phase of research. Please feel free to contact us, if you have any special needs in the field of hit identification for ophthalmic drug discovery. We look forward to working with you in the future.

• Target ID and Validation Services for Small Molecule Ophthalmic Drug
• Hit to Lead Services for Small Molecule Ophthalmic Drug
• Lead Optimization Services for Small Molecule Ophthalmic Drug

• * Name:
• Phone:
• * Email:
• * Services or Products of Interest:
• Project Description:
• * All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

  * Tick to confirm the Research Use Only (RUO) statement.

• Submit